11th Immunotherapy of Cancer conference (ITOC): A meeting report

Stefanos Michaelides1, Viktoria Hartmann1, Volkmar Nüssler2

  • 1Division of Clinical Pharmacology, LMU University Hospital, LMU Munich, Munich, Germany.

The Immunotherapy of Cancer (ITOC) meeting is an international conference providing a platform for immuno-oncologists worldwide to present and discuss their research and newest findings. Being held in Munich annually, the 11th edition took place in April 2025 and saw broad discussions about new concepts in the field of immuno-oncology, mixed with exciting clinical results but also with a glimpse back into the past. This was mirrored by the lifetime achievement award, given to Robert D. Schreiber for his groundbreaking work on the immune surveillance of cancer. ITOC11 impressively showcase how far immuno-oncology has come in a conference extending from the discipline's very beginnings up to some of the most exciting new findings in the field of cancer immunology. The conference has demonstrated that tumor immunology is not only about cancer and immune cells, but extends far beyond.

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...